Member Info for miti1000

Well, clearly the prospects for savo are looking pretty good. Azn seem to pretty happy and hcm want to get a bigger share of future royalties so committing another $50milion..suggest the data from the trial is going to be very good. Only negative I can see is no mention of early NDA possibility based on phase 2 rather than phase 3. Perhaps they will touch upon that tomorrow.

Matt, Still here, busy trading away in my day job . I made it to the agm....was quite happy with what I heard and have added since then . Obviously ,the only thing that is going to move this are the savo trials in the autumn .Not much to say till then.

Unfortunately , won't be able to attend the Agm . Results calendar on Wednesday just too manic to tear me away from trading them.

Ok , I'm mainly interested in the pipeline of news this year and how confident they are and why the drug news has been slightly delayed. Will catch him on his own after the meeting rather than ask during the agm. They tend to be much more forthcoming in one to one's so don't rush off once the agm meeting is over.

https://edge.media-server.com/m/p/ip3kdsmm/

davey, I'll be going to the agm .

Sadly , yes, sterling!!

Matt, Fair point and clearly I've been too bullish on HCM as it turns out. At the same time , in October the biotech index was strong and the IPO market was strong in the US. Since then both have weakened considerably . As regards valuations, HCM remains cheap and now cheaper still than relative comparitives. We will have to await good drug trials in Q2 2016 and later on to hopefully close this gap. As far as I'm aware, nothing untoward has gone wrong with HCM so I remain invested , albeit 400k underwater on it.

March 29, 2016 7:30 am Chi-Med taps Nasdaq for $100m to help break innovation drought Andrew Ward, Pharmaceuticals Correspondent A $100m Nasdaq flotation has given a fresh impetus to efforts by Hutchison China MediTech to produce the first drug to originate from China for decades. Christian Hogg, Chi-Med chief executive, said the initial public offering, which was completed last week, would support work on two cancer drugs being developed in partnership with AstraZeneca and Eli Lilly as well as several others at earlier stages. More ON THIS TOPIC Chi-Med poised for China drug milestone Chi-Med draws on the past for the future The company, which is 65 per cent-controlled by Li Ka-shing’s CK Hutchison group, is the second Chinese drug developer to list in New York this year after Beigene raised $158m last month. China has not produced a new medicine for the global market since artemisinin for malaria in the 1970s — a breakthrough for which chemist Tu Youyou was awarded a Nobel Prize last year. Mr Hogg said Chi-Med could end this innovation drought if clinical data due this year from a trial of savolitinib — a kidney cancer therapy co-developed with AstraZeneca of the UK — was good enough to file for approval with US regulators. “The Chinese biotech industry is evolving and we are starting to see companies come through,” said Mr Hogg, a Briton who has run the Hong Kong-based company for a decade. “We are in China but we are developing for the global market.” Another drug called fruquintinib for colorectal cancer, co-developed with Eli Lilly, is also in late-stage development and five others are in earlier stage clinical trials. One of the most promising — a treatment called HMPL-523 for blood cancers and rheumatoid arthritis — is a potential rival for blockbuster drugs including AbbVie’s Humira and Imbruvica. Chi-Med’s New York IPO adds to the listing it has had on London’s junior Aim bourse for the past 10 years. Mr Hogg said UK institutional investors would remain the “foundation” of the company but he admitted to frustrations with Aim. “The main reason for the Nasdaq listing is to get in front of specialist biotech investors who can value the Nasdaq listing is to get in front of specialist biotech investors who can value the company properly,” he said. “The issue with Aim is liquidity. Nobody trades shares. As a result, there’s no analyst coverage. When you have a big investor base they need to be able to read analyst research.” Chi-Med raised $101.25m through the sale of 7.5m American Depositary Shares at $13.50 each. The IPO was oversubscribed but priced at a discount to the London share price, reflecting the difficult market conditions which have sharply slowed the flow of IPOs this year. Dozens of European life science companies have listed on Nasdaq ov

Thanks for that. Also an article in Ft on HCM including some comments from the CEO.

Well, got that well and truly wrong...into the LTBH draw she goes and hopefully value will out at some point.

Yes, looks like the US investors have squeezed them fr their pound of flesh and automatic profit on their allocations. Frustrating , for sure but not end of world in medium term. Short term, not ideal!!

As an aside, I'm surprised the MM's have not gone to SETS on HCM. Hopefully they will by Thursday.

Yes, I should be able to make if I can get away from my trading screens .Will let you know closer to the time. Should be a very interesting agm. We are due the PRCC phase II results anytime from April onwards which is probably why they've delayed the listing till now.They will be pivotal to increasing awareness in the US. On your question on the uk price....they should follow but in reality , there's normally always a discount lag in the uk price going forward . Nevertheless, like you , I'm expecting a sharp spike in the uk price once it lists on Thursday. I'm hoping the US Adr will be well over $22 dollars within the next month and stay there, if not higher.

Matt the S...Scared , are you still worried it won't float ? Or are you singing a different tune now ?

A slight delay in the timings of drug news but we should get before June. Results were fine. As a results of Friday's news , we should have the Nasdaq IPO within 2 months and hopefully much sooner judging by past ipo's from here. Once on Nasdaq, I'm expecting the US biotech investors will be piling into HCM. Matt the Sh..scared , any comment ? Beigene is now up over 34% since its IPO and its more like a start up in comparison to HCM imo.

Well, we have results on Tuesday .Everything on timing should be much clearer then. BGNE closed on Friday at about 23% above its float price which is excellent. That augers well for a March float for HCM.

Beigene flying in the US ...trading at over 28 dollars fyi

Having spoken to Mr Hogg, he's assured me its all on track . Beigene IPO is this week so if that goes fine , we should be set fair. Beigene is very poor quality float in comparison to HCM imo so fingers crossed it stays above $24 if the Reuters article is correct.

Beigene ipo priced at top of range it seems.They also have raised more than they were aiming for. http://www.reuters.com/article/beigene-ipo-idUSL2N15I049